NR2F6 and melanoma: Notably, compared with NR2F6 WT B16F10 cells, NR2F6 KD via either one of two shRNAs (Fig. 2A) led to 43.2% (sh226) or 68.7% (sh194) inhibition of B16F10 melanoma growth in immune-competent (C57BL/6) but not immune-incompetent [Nod-Scid-Gamma (NSG)] mice compared to cells harboring WT NR2F6 (fig.